David Szekeres
2022
In 2022, David Szekeres earned a total compensation of $1.4M as Executive Vice President, Chief Commercial Officer at Heron Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $199,880 |
---|---|
Option Awards | $235,482 |
Salary | $533,013 |
Stock Awards | $441,456 |
Other | $19,400 |
Total | $1,429,231 |
Szekeres received $533K in salary, accounting for 37% of the total pay in 2022.
Szekeres also received $199.9K in non-equity incentive plan, $235.5K in option awards, $441.5K in stock awards and $19.4K in other compensation.
Rankings
In 2022, David Szekeres' compensation ranked 2,327th out of 5,760 executives tracked by ExecPay. In other words, Szekeres earned more than 59.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,327 out of 5,760 | 60th |
Division Manufacturing | 1,266 out of 3,136 | 60th |
Major group Chemicals And Allied Products | 566 out of 1,422 | 60th |
Industry group Drugs | 521 out of 1,323 | 61st |
Industry Pharmaceutical Preparations | 377 out of 969 | 61st |
Source: SEC filing on May 1, 2023.
Szekeres' colleagues
We found two more compensation records of executives who worked with David Szekeres at Heron Therapeutics in 2022.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021